Personalized medicine for glioblastoma: Current challenges and future opportunities

Current Molecular Medicine

Volumn 13, Issue 3, 2013, Pages 358-367

  Zhu, J J ^a   Wong, E T ^b  

^a MEMORIAL HERMANN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glioblastoma; IDH1 mutation; MicroRNA; Personalized medicine; Tumor heterogeneity

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; 2 HYDROXYGLUTARIC ACID; ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 107; MICRORNA 10B; MICRORNA 124; MICRORNA 16; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 9; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; SCATTER FACTOR RECEPTOR; VASCULOTROPIN;

ARTICLE; CLINICAL TRIAL (TOPIC); CPG ISLAND; DISEASE CLASSIFICATION; DOWN REGULATION; EPIGENETICS; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; NEUROFIBROMATOSIS; NEUROLOGY; ONCOLOGY; PERSONALIZED MEDICINE; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84877763967     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652413805076795     Document Type: Article

References (82)

1. States CBTRotU. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008. Hinsdale, IL. 2012; Available from: www.cbtrus.org.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009; 10(5): 459-66.
3. Wong ET, Brem S. Taming glioblastoma by targeting angiogenesis: 3 years later. J Clin Oncol 2011; 29(2): 124-6.
4. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70(10): 779-87.
5. Gao C, Furge K, Koeman J, et al. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci USA 2007; 104(21): 8995-9000.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031-7.
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7): 472-80.
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-39.
9. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17(9): 2639-48.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235-42.
11. Masui K, Cloughesy TF, Mischel PS. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012; 38(3): 271-91.
12. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455(7216): 1061-8.
13. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1): 98-110.
14. Greaves M. Cancer stem cells: back to Darwin? Semin Cancer Biol 2010; 20(2): 65-70.
15. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4): 683-92.
16. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007; 61(5 Pt 2): 24R-9R.
17. Hegi ME, Liu L, Herman JG, et al. Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26(25): 4189-99.
18. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483(7390): 479-83.
19. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17(5): 510-22.
20. Tepel M, Roerig P, Wolter M, et al. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 2008; 123(9): 2080-6.
21. Gotze S, Wolter M, Reifenberger G, Muller O, Sievers S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 2010; 126(11): 2584-93.
22. Nakamura M, Ishida E, Shimada K, et al. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 2005; 85(2): 165-75.
23. Kunitz A, Wolter M, van den Boom J, et al. DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. Brain Pathol 2007; 17(4): 363-70.
24. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 2001; 81(1): 77-82.
25. Nakamura M, Watanabe T, Klangby U, et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001; 11(2): 159-68.
26. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293(5532): 1074-80.
27. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321(5897): 1807-12.
28. Lucio-Eterovic AK, Cortez MA, Valera ET, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008; 8: 243.
29. Campos B, Bermejo JL, Han L, et al. Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 2011; 102(2): 387-92.
30. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483(7390): 474-8.
31. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65(14): 6029-33.
32. Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008; 68(10): 3566-72.
33. Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007; 6(16): 2005-9.
34. Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.
35. Cui JG, Zhao Y, Sethi P, et al. Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation. J Neurooncol 2010; 98(3): 297-304.
36. Gabriely G, Yi M, Narayan RS, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res 2011; 71(10): 3563-72.
37. Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PloS One 2011; 6(3): e17438.
38. Godlewski J, Newton HB, Chiocca EA, Lawler SE. MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ 2010; 17(2): 221-8.
39. Gabriely G, Teplyuk NM, Krichevsky AM. Context effect: microRNA-10b in cancer cell proliferation, spread and death. Autophagy 2011; 7(11): 1384-6.
40. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197(4306): 893-5.
41. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366(10): 883-92.
42. Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 2012; 109(8): 3041-6.
43. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462(7274): 739-44.
44. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2- hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012; 4(116): 116ra4.
45. Struys EA, Salomons GS, Achouri Y, et al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2- hydroxyglutaric aciduria. Am J Hum Genet 2005; 76(2): 358-60.
46. Locasale JW, Melman T, Song S, et al. Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma. Mol Cell Proteomics 2012; 11(6): M111.014688.
47. Balaj L LE, Swanson KD, Asara JM, et al. Malignant Glioma Genotyping by CSF 2-Hydroxyglutarate Oncometabolite and IDH1 Mutation Analysis. Ann Neurol 2012; 72(Suppl 16): S121-32.
48. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22(1): 133-42.
49. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009; 27(8): 1268-74.
50. Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2012; 2(5): 458-71.
51. Barkovich KJ, Hariono S, Garske AL, et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov 2012; 2(5): 450-7.
52. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Transl Med 2011; 3(75): 75ra26.
53. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4(120): 120ra17.
54. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17(1): 77-88.
55. Lu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22(1): 21-35.
56. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99(2): 283-6.
57. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007; 13(5): 1511-5.
58. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28(31): 4722-9.
59. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48(14): 2192-202.
60. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5(9): 689-98.
61. See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cisretinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol 2004; 6(3): 253-8.
62. Kast RE, Karpel-Massler G, Halatsch ME. Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? Br J Pharmacol 2011; 164(5): 1393-6.
63. Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond) 2010; 7: 33.
64. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11(12): 849-64.
65. Pang JC, Kwok WK, Chen Z, Ng HK. Oncogenic role of microRNAs in brain tumors. Acta Neuropathol 2009; 117(6): 599-611.
66. Schraivogel D, Weinmann L, Beier D, et al. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J 2011; 30(20): 4309-22.
67. Lang MF, Yang S, Zhao C, et al. Genome-Wide Profiling Identified a Set of miRNAs that Are Differentially Expressed in Glioblastoma Stem Cells and Normal Neural Stem Cells. PloS One 2012; 7(4): e36248.
68. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005; 334(4): 1351-8.
69. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 2008; 68(22): 9125-30.
70. Guan Y, Mizoguchi M, Yoshimoto K, et al. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 2010; 16(16): 4289-97.
71. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18(3): 350-9.
72. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 2010; 107(5): 2183-8.
73. Silber J, Jacobsen A, Ozawa T, et al. miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis. PloS One 2012; 7(3): e33844.
74. Fang L, Deng Z, Shatseva T, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 2011; 30(7): 806-21.
75. Papagiannakopoulos T, Friedmann-Morvinski D, Neveu P, et al. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene 2012; 31(15): 1884-95.
76. Xu J, Liao X, Lu N, Liu W, Wong CW. Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines. Int J Cancer 2011; 129(10): 2527-31.
77. D'Urso PI, D'Urso OF, Storelli C, et al. miR-155 is upregulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. Int J Oncol 2012; 41(1): 228-34.
78. Zhang Z, Tang H, Wang Z, et al. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer 2011; 10: 124.
79. Yue X, Wang P, Xu J, et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep 2012; 27(4): 1200-6.
80. Gal H, Pandi G, Kanner AA, et al. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun 2008; 376(1): 86-90.
81. Wang L, Shi M, Hou S, et al. MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett 2012; 586(9): 1312-7.
82. Yan W, Zhang W, Sun L, et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 2011; 1411: 108-15.